Get the Stockscreener App
3.68
6.84%
-0.27
After Hours:
3.75
0.07
+1.90%
Exagen Inc stock is traded at $3.68, with a volume of 1.36M.
It is down -6.84% in the last 24 hours and down -38.77% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$3.95
Open:
$3.95
24h Volume:
1.36M
Relative Volume:
2.96
Market Cap:
$83.40M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-3.9149
EPS:
-0.94
Net Cash Flow:
$-15.29M
1W Performance:
-20.00%
1M Performance:
-38.77%
6M Performance:
-57.36%
1Y Performance:
-10.24%
1-Day Range:
$3.525
$3.95
1-Week Range:
$3.525
$4.69
52-Week Range:
$2.77
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.68 | 89.52M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
B. Riley Cuts Price Target on Exagen to $8 From $18, Keeps Buy Rating - marketscreener.com
XGN: B. Riley Securities Lowers Price Target, Maintains Buy Rati - GuruFocus
Exagen's (XGN) "Buy" Rating Reaffirmed at B. Riley - MarketBeat
Is Exagen Inc. impacted by rising rates2025 Volume Leaders & High Accuracy Investment Signals - mfd.ru
What are Exagen Inc.’s recent SEC filings showingWeekly Gains Summary & Weekly Return Optimization Plans - mfd.ru
How The Exagen (XGN) Story Is Shifting With A New Analyst Price Target - Yahoo Finance
Volume Recap: Does Crescent Capital BDC Inc stock reflect fundamentals2025 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
Benign Growth For Exagen Inc. (NASDAQ:XGN) Underpins Stock's 26% Plummet - 富途牛牛
Trend Report: Will Exagen Inc benefit from current market trendsTrade Entry Summary & Daily Chart Pattern Signals - baoquankhu1.vn
Exagen Inc. (NASDAQ:XGN) Sees Large Growth in Short Interest - MarketBeat
Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28% - Sahm
Selling Exagen Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Sahm
Tech Rally: Is Exagen Inc. benefiting from innovation trends2025 Trading Volume Trends & Breakout Confirmation Alerts - baoquankhu1.vn
Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
ETF Watch: How Exagen Inc stock benefits from global expansionJuly 2025 Technicals & Community Consensus Stock Picks - Bộ Nội Vụ
Published on: 2026-01-13 10:11:31 - ulpravda.ru
Analysts Are Bullish on These Healthcare Stocks: Exagen (XGN), Medline, Inc. Class A (MDLN) - The Globe and Mail
How Recent Analyst Resets Are Reframing The Exagen (XGN) Investment Story - Yahoo Finance
Exagen Announces Record 2025 Revenue and Strong Cash Position - TipRanks
Canaccord Genuity maintains Buy rating on Exagen stock amid ASP challenges - Investing.com Canada
California-based Exagen preliminary revenue up 19% in FY25 - Medical Buyer
Exagen (XGN) Reports Strong Annual Growth and Strategic Advances - GuruFocus
Exagen Inc. Reports Preliminary Financial Results for Q4 and Full Year 2025, Highlighting Record Revenue Growth - Quiver Quantitative
Exagen Inc. Announces Select Preliminary 2025 Financial Results - Bluefield Daily Telegraph
Autoimmune testing firm Exagen ends 2025 with record sales and more cash - Stock Titan
Why Exagen Inc. stock could rally in 2025Forecast Cut & Real-Time Sentiment Analysis - Улправда
T Inc Class stock compares with tech leaders2025 Top Gainers & Safe Capital Allocation Plans - ulpravda.ru
Aug Macro: What margin trends mean for Exagen Inc. stockMarket Growth Review & Long-Term Safe Return Strategies - ulpravda.ru
Is Exagen Inc. stock positioned well for digital economyMarket Trend Summary & High Accuracy Swing Entry Alerts - ulpravda.ru
What margin trends mean for Exagen Inc. stockEarnings Growth Summary & Weekly Market Pulse Alerts - ulpravda.ru
What makes Exagen Inc. stock attractive to growth funds2025 Market Overview & Stock Portfolio Risk Management - ulpravda.ru
Revenue Check: Can Huron Consulting Group Inc. stock deliver surprise earnings beat2025 Macro Impact & AI Forecast Swing Trade Picks - ulpravda.ru
2026 world cup usa squad group stage veteran players set piece strategy knockout prediction analysis - ulpravda.ru
ulpravda ru > 2026> Will LIMN stock beat EPS estimatesQuarterly Trade Summary & High Conviction Buy Zone Picks - ulpravda.ru
Will Exagen Inc. stock outperform Dow Jones indexJuly 2025 Catalysts & Long-Term Safe Return Strategies - Улправда
Will Exagen Inc. (E08A) stock split increase liquidityEarnings Risk Report & Stepwise Trade Signal Implementation - ulpravda.ru
How ImmunityBio Inc. stock trades before earningsJuly 2025 Sector Moves & Real-Time Market Trend Scan - ulpravda.ru
Can Exagen Inc. (E08A) stock reach $200 price targetWeekly Gains Report & Community Consensus Picks - Улправда
Is MIMI stock a smart buy before Fed meetingWeekly Trade Summary & Low Risk High Reward Ideas - ulpravda.ru
ulpravda ru > 2026> Is BPYPO stock dividend yield sustainableMarket Risk Analysis & Fast Entry High Yield Tips - ulpravda.ru
Will Exagen Inc. (E08A) stock rise with strong economyMarket Risk Analysis & Daily Risk Controlled Trade Plans - ulpravda.ru
What momentum indicators show for Exagen Inc. stock2025 Big Picture & Weekly High Return Stock Opportunities - ulpravda.ru
Will Exagen Inc. stock benefit from AI adoption2025 Volatility Report & Verified Short-Term Plans - Улправда
How Exagen Inc. stock reacts to job market dataTrade Execution Strategies & Free Rapid Portfolio Appreciation - Улправда
Why Exagen Inc stock could rally in 2025Market Risk Analysis & Real-Time Price Movement Reports - Bộ Nội Vụ
Free cash flow per share of Exagen, Inc. – SWB:E08A - TradingView — Track All Markets
Exagen Inc E08A Stock Analysis and ForecastTrendline Breakouts & Compound Your Gains With Quality Stocks - earlytimes.in
XGN Stock Price, Forecast & Analysis | EXAGEN INC (NASDAQ:XGN) - Chartmill
American Bio Medica (OTCMKTS:ABMC) versus Exagen (NASDAQ:XGN) Head-To-Head Comparison - Defense World
Will Exagen Inc. stock see PE expansionFibonacci Extensions & Build Wealth With Strategy - bollywoodhelpline.com
Will Exagen Inc. stock benefit from automationDividend Yield Trends & Technical + Fundamental = Smarter Investing - bollywoodhelpline.com
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):